专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO0206479A2 APOPTOSIS-INDUCING DNA SEQUENCES 审中-公开
标题翻译：细胞凋亡诱导的DNA序列
公开(公告)号：WO0206479A2
公开(公告)日：2002-01-24
申请号：PCT/EP0108170
申请日：2001-07-13
申请人： MAX PLANCK GESELLSCHAFT , GRIMM STEFAN , SCHOENFELD NICOLE , BRAZIULIS ERIK , CRAMER URSULA , GEWIES ANDREAS , VOSS FRANK , MUND THOMAS , ALBAYRAK TIMUR , GILLE HENDRIK , KLEIN MATTHIAS
发明人： GRIMM STEFAN , SCHOENFELD NICOLE , BRAZIULIS ERIK , CRAMER URSULA , GEWIES ANDREAS , VOSS FRANK , MUND THOMAS , ALBAYRAK TIMUR , GILLE HENDRIK , KLEIN MATTHIAS
IPC分类号： A61K38/00 , A61K48/00 , C07K14/47 , C12N15/12 , A01K67/027 , A61K38/17 , C12N5/06 , C12Q1/68 , G01N33/68
CPC分类号： C07K14/4747 , A01K2217/05 , A61K38/00 , A61K48/00
摘要： The invention relates to novel apoptosis-associated and especially apoptosis-inducing nucleic acid sequences, polypeptides which are coded by said sequences, and the use of the same for preparing diagnostic and therapeutic agents. The invention also relates to cell systems, transgenic animals and the use thereof for genetic and/or pharmacological research into apoptosis-associated illnesses.
摘要翻译：本发明涉及新的细胞凋亡相关，特别是诱导细胞凋亡的核酸序列，多肽编码以及它们在提供诊断和治疗剂的用途。另外，本发明的细胞的系统和转基因动物和它们对细胞凋亡相关疾病的遗传和/或药理学研究用途涉及。

2. 发明申请

WO2004111088A2 A NEW ANGIOGENIC FACTOR AND ITS INHIBITORS 审中-公开
标题翻译：生物因子及其抑制剂
公开(公告)号：WO2004111088A2
公开(公告)日：2004-12-23
申请号：PCT/EP2004/006265
申请日：2004-06-09
申请人： XANTOS BIOMEDICINE AG , GILLE, Hendrik , GAWIN, Beate , SCHÄFER, Rolf , HESS, Stephan , KORHERR, Christian , BOCHE, Irene , WALTER, Theresia , GNIRKE, Andreas
发明人： GILLE, Hendrik , GAWIN, Beate , SCHÄFER, Rolf , HESS, Stephan , KORHERR, Christian , BOCHE, Irene , WALTER, Theresia , GNIRKE, Andreas
IPC分类号： C07K14/515
CPC分类号： C07K14/515 , A61K38/00
摘要： The present invention relates to a novel angiogenic factor, SEP, as well as to soluble derivatives thereof and to their use in pharmaceutical or diagnostic compositions.
摘要翻译：本发明涉及新型血管发生因子SEP及其可溶性衍生物的抑制剂及其在药物组合物中的用途。

3. 发明申请

WO2002006479A3 APOPTOSE-INDUZIERENDE DNA-SEQUENZEN 审中-公开
公开(公告)号：WO2002006479A3
公开(公告)日：2002-01-24
申请号：PCT/EP2001/008170
申请日：2001-07-13
申请人： MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WISSENSCHAFTEN E.V. , GRIMM, Stefan , BAUER Manuel , SCHÖNFELD, Nicole , BRAZIULIS, Erik , CRAMER, Ursula , GEWIES, Andreas , VOSS, Frank , MUND, Thomas , ALBAYRAK, Timur , GILLE, Hendrik , KLEIN, Matthias
发明人： GRIMM, Stefan , BAUER Manuel , SCHÖNFELD, Nicole , BRAZIULIS, Erik , CRAMER, Ursula , GEWIES, Andreas , VOSS, Frank , MUND, Thomas , ALBAYRAK, Timur , GILLE, Hendrik , KLEIN, Matthias
IPC分类号： C12N15/12
摘要： Die Erfindung betrifft neue Apoptose-assoziierte und insbesondere Apoptose-induzierende Nukleinsäuresequenzen, davon codierte Polypeptide und deren Verwendung zur Bereitstellung diagnostischer und therapeutischer Mittel. Zusätzlich betrifft die Erfindung Zellsysteme sowie transgene Tiere und deren Verwendung zur genetischen und/oder pharmakologischen Untersuchung von Apoptose-assoziierten Krankheiten.

4. 发明申请

WO2011015634A3 CONTROLLED RELEASE FORMULATIONS OF LIPOCALIN MUTEINS 审中-公开
公开(公告)号：WO2011015634A3
公开(公告)日：2011-02-10
申请号：PCT/EP2010/061436
申请日：2010-08-05
申请人： PIERIS AG , HOHLBAUM, Andreas , HUELSMEYER, Martin , GILLE, Hendrik , MANTRIPRAGADA, Sankaram, Bhima , CAMPBELL, Kathleen, Marie
发明人： HOHLBAUM, Andreas , HUELSMEYER, Martin , GILLE, Hendrik , MANTRIPRAGADA, Sankaram, Bhima , CAMPBELL, Kathleen, Marie
IPC分类号： A61K9/16 , A61K9/00 , A61K38/00 , A61K47/48 , C07K14/47
摘要： The present invention relates to pharmaceutical compositions for the controlled release of lipocalin muteins and conjugates thereof with a moiety selected from the group consisting of a protein, protein domain, peptide, lipid, fatty acid, polysaccharide and/or an organic polymer that comprise said lipocalin mutein of conjugate thereof in combination with a biodegradable polymer. The invention further relates to a method for the controlled delivery of the lipocalin muteins or conjugates thereof, methods for the production of a controlled release formulation and the thus produced formulation. Finally, the invention is directed to the use of the formulations of the invention for the controlled delivery of the lipocalin mutein, for extending the in vivo half-life of the lipocalin mutein, for increasing the bioavailability of the lipocalin mutein, or for decreasing the immunogenicity of the lipocalin mutein upon administration to a subject as well as methods for the treatment of a disease or disorder comprising the administration of the formulations of the invention to a subject in need thereof.

5. 发明申请

WO2011015634A2 CONTROLLED RELEASE FORMULATIONS OF LIPOCALIN MUTEINS 审中-公开
标题翻译： LIPOCALIN MUTEINS的控制释放配方
公开(公告)号：WO2011015634A2
公开(公告)日：2011-02-10
申请号：PCT/EP2010061436
申请日：2010-08-05
申请人： PIERIS AG , HOHLBAUM ANDREAS , HUELSMEYER MARTIN , GILLE HENDRIK , MANTRIPRAGADA SANKARAM BHIMA , CAMPBELL KATHLEEN MARIE
发明人： HOHLBAUM ANDREAS , HUELSMEYER MARTIN , GILLE HENDRIK , MANTRIPRAGADA SANKARAM BHIMA , CAMPBELL KATHLEEN MARIE
CPC分类号： A61K9/0019 , A61K9/1647 , A61K47/60 , C07K14/47
摘要： The present invention relates to pharmaceutical compositions for the controlled release of lipocalin muteins and conjugates thereof with a moiety selected from the group consisting of a protein, protein domain, peptide, lipid, fatty acid, polysaccharide and/or an organic polymer that comprise said lipocalin mutein of conjugate thereof in combination with a biodegradable polymer. The invention further relates to a method for the controlled delivery of the lipocalin muteins or conjugates thereof, methods for the production of a controlled release formulation and the thus produced formulation. Finally, the invention is directed to the use of the formulations of the invention for the controlled delivery of the lipocalin mutein, for extending the in vivo half-life of the lipocalin mutein, for increasing the bioavailability of the lipocalin mutein, or for decreasing the immunogenicity of the lipocalin mutein upon administration to a subject as well as methods for the treatment of a disease or disorder comprising the administration of the formulations of the invention to a subject in need thereof.
摘要翻译：本发明涉及用于将脂质运载蛋白突变蛋白及其结合物与选自蛋白质，蛋白质结构域，肽，脂质，脂肪酸，多糖和/或包含所述脂质运载蛋白的有机聚合物的部分控制释放的药物组合物其缀合物的突变蛋白与可生物降解的聚合物组合。本发明还涉及用于控制递送脂质运载蛋白突变蛋白或其缀合物的方法，用于生产受控释放制剂的方法和由此制备的制剂。最后，本发明涉及本发明的制剂用于控制递送脂质运载蛋白突变蛋白的用途，用于延长脂质运载蛋白突变蛋白的体内半衰期，以提高脂质运载蛋白突变蛋白的生物利用度，或用于降低给予受试者的脂质运载蛋白突变蛋白的免疫原性以及治疗疾病或病症的方法，包括将本发明的制剂施用于有需要的受试者。

6. 发明申请

WO2004111088A3 ANGIOGENIC FACTOR AND INHIBITORS THEREOF 审中-公开
标题翻译：生物因子及其抑制剂
公开(公告)号：WO2004111088A3
公开(公告)日：2005-02-10
申请号：PCT/EP2004006265
申请日：2004-06-09
申请人： XANTOS BIOMEDICINE AG , GILLE HENDRIK , GAWIN BEATE , SCHAEFER ROLF , HESS STEPHAN , KORHERR CHRISTIAN , BOCHE IRENE , WALTER THERESIA , GNIRKE ANDREAS
发明人： GILLE HENDRIK , GAWIN BEATE , SCHAEFER ROLF , HESS STEPHAN , KORHERR CHRISTIAN , BOCHE IRENE , WALTER THERESIA , GNIRKE ANDREAS
IPC分类号： A61K38/00 , C07K14/515 , C07K14/47 , A61K38/17
CPC分类号： C07K14/515 , A61K38/00
摘要： The present invention relates to inhibitors of a novel angiogenic factor, SEP, and soluble derivatives thereof and to their use in pharmaceutical compositions.
摘要翻译：本发明涉及新型血管发生因子SEP及其可溶性衍生物的抑制剂及其在药物组合物中的用途。

7. 发明申请

WO2004111085A1 ANGIOGENIC FACTOR AND ITS MEDICAL USE 审中-公开
标题翻译：生殖因子及其医疗用途
公开(公告)号：WO2004111085A1
公开(公告)日：2004-12-23
申请号：PCT/EP2004/006270
申请日：2004-06-09
申请人： XANTOS BIOMEDICINE AG , GILLE, Hendrik , GAWIN, Beate , SCHÄFER, Rolf , HESS, Stephan , KORHERR, Christian
发明人： GILLE, Hendrik , GAWIN, Beate , SCHÄFER, Rolf , HESS, Stephan , KORHERR, Christian
IPC分类号： C07K14/47
CPC分类号： C07K14/515 , A61K38/00
摘要： The present invention relates to a novel angiogenic factor, SEP, as well as to soluble derivatives thereof and to their use in pharmaceutical or diagnostic compositions.
摘要翻译：本发明涉及新型血管生成因子SEP，以及其可溶性衍生物及其在药物或诊断组合物中的用途。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式